Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 10/20 | 0.62 |
| ▸ | SLC16A1 | P53985 | 6/20 | 0.62 |
| ▸ | MCTS1 | Q9ULC4 | 5/20 | 0.62 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | FABP2 | P12104 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2221138 | 0.87 | SLC16A3 (0.53) | SLC16A3SLC16A1MCTS1PPARG | |
| SCHEMBL11653742 | 0.82 | PPARA (0.49) | SLC16A3SLC16A1MCTS1PPARAMEN1 | |
| SCHEMBL10840399 | 0.81 | MAOA (0.49) | SLC16A3SLC16A1MCTS1PPARAMEN1 | |
| SCHEMBL11228891 | 0.81 | MEN1 (0.47) | SLC16A3SLC16A1MCTS1PPARAMEN1 | |
| Clobuzarit SCHEMBL8700294 | 0.80 | ACE (0.53) | SLC16A3SLC16A1MCTS1PPARAPPARG | |
| SCHEMBL883026 | 0.79 | SLC16A3 (0.55) | SLC16A3SLC16A1MCTS1PPARAKMT2A | |
| SCHEMBL11657373 | 0.78 | PPARA (0.48) | SLC16A3SLC16A1MCTS1PPARAMEN1 | |
| SCHEMBL2215266 | 0.78 | RXRA (0.46) | SLC16A3SLC16A1MCTS1PPARAMAPT | |
| SCHEMBL2352150 | 0.78 | RXRA (0.46) | SLC16A3SLC16A1MCTS1PPARACYP3A4 | |
| SCHEMBL8935661 | 0.78 | SLC16A3 (0.46) | SLC16A3SLC16A1MCTS1PPARAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752201-B1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | UNIV FRIEDRICH ALEXANDER ER (DE) | 2023-11-22 | — | — | EP | claimed |
| EP-3752201-A1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-12-23 | — | — | EP | claimed |
| WO-2019158509-A1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2019-08-22 | — | — | WO | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| US-9161927-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-20 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014111957-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | SATYAM APPARAO (IN) | 2014-07-24 | — | — | WO | claimed |
| US-8759326-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | claimed |
| EP-1200110-B1 | IN VIVO INDUCTION FOR ENHANCED FUNCTION OF ISOLATED HEPATOCYTES | ORGANOGENESIS INC (US) | 2014-04-23 | — | — | EP | claimed |
| US-20140031343-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| US-20020085995-A1 | In vivo induction for enhanced function of isolated hepatocytes | SILICON VALLEY BANK | 2002-07-04 | — | — | US | claimed |
| US-6394812-B1 | LIVER CELL CULTURE | ORGANOGENESIS INC. | 2002-05-28 | — | — | US | claimed |
| EP-1200110-A1 | IN VIVO INDUCTION FOR ENHANCED FUNCTION OF ISOLATED HEPATOCYTES | ORGANOGENESIS INC. (US) | 2002-05-02 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2001007069-A1 | IN VIVO INDUCTION FOR ENHANCED FUNCTION OF ISOLATED HEPATOCYTES | ORGANOGENESIS INC. (US) | 2001-02-01 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| EP-0037697-B1 | DIOXOLANE DERIVATIVES FOR USE AS CHEMICAL INTERMEDIATES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-08-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031343-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | PTGER4, PDE4A, PDE12 | SLC16A3 3332/4885SLC16A1 4014/4885MCTS1 3799/4885 |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | SLC16A3 1611/4885SLC16A1 1356/4885MCTS1 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.